Tempus AI's Legal Chief Sells Shares Amid Stock Rally
Andrew Polovin, Tempus AI’s Executive Vice President and Chief Legal Officer, sold 30,075 shares of the company at $51.29 per share in a transaction totaling $1.5 million. The sale was non-discretionary and executed to cover tax obligations tied to restricted stock units vesting under a Rule 10b5-1 trading plan established on August 12, 2025. The company’s stock has rallied about 75% since late last month but remains roughly 30% below its all-time high. The recent surge was not driven by Tempus AI itself but rather news from a Moderna and Merck cancer vaccine trial that validated genomic sequencing technology relevant to the company's pending $1.5 billion Personalis deal. Tempus AI reported revenue of $382.5 million in its last quarter, up 22%, marking its first GAAP profit. Despite this progress, the firm remains unprofitable on a trailing twelve-month basis with net income at -$254.4 million as it continues to invest in growth.
